Long term effects of anti-VEGF agents: patho-physiological perspectives

Authors

  • M Gupta Department of Physiology, JN Medical College Aligarh Muslim University, Aligarh
  • Y Gupta Institute of Ophthalmology, JN Medical College, Aligarh Muslim University, Aligarh
  • A Phougat Institute of Ophthalmology, JN Medical College, Aligarh Muslim University, Aligarh

DOI:

https://doi.org/10.3126/nepjoph.v5i1.7834

Keywords:

VEGF, ranibizumab, revacizumab

Abstract

Monoclonal antibodies directed against different targets have become a new tool for the treatment of various disorders. More than 20 monoclonal antibody-based therapies have been approved in the USA and hundreds more are in development. Some of these therapies are finding applications in ocular disorders. The role of anti-VEGF in the treatment of wet ARMD is now well known. Anti-VEGF, which were initially discovered to treat carcinomas like bevacizumab in metastatic colorectal carcinoma, have now found place in ophthalmology to treat disorders where neovascularization/angiogenesis leads to blindnes.

Nepal J Ophthalmol 2013; 5(9):100-105

DOI: http://dx.doi.org/10.3126/nepjoph.v5i1.7834

Downloads

Download data is not yet available.
Abstract
747
PDF
590

Downloads

Published

2013-03-26

How to Cite

Gupta, M., Gupta, Y., & Phougat, A. (2013). Long term effects of anti-VEGF agents: patho-physiological perspectives. Nepalese Journal of Ophthalmology, 5(1), 100–105. https://doi.org/10.3126/nepjoph.v5i1.7834

Issue

Vol. 5 No. 1 (2013)

Section

Review Article

License

This license enables reusers to copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator.